The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Non-injectable Insulin Global Market Report 2024, the non-injectable insulin market is expected to show significant growth in the forecast period.

Expanding Non-Injectable Insulin Market Fueled By Escalating Obesity And Diabetes Epidemics

The non-injectable insulin market has witnessed rapid growth, driven by its expanding application in treating diabetes and obesity. In 2023, the market size reached $1.71 billion and is projected to grow to $1.92 billion in 2024, reflecting a compound annual growth rate (CAGR) of 12.2%. This growth is attributed to advancements enhancing patient compliance, addressing needle phobia, improving quality of life, easing administration, and stabilizing blood glucose levels.

Future Growth and Key Trends

The market is expected to continue its robust growth, reaching $2.89 billion by 2028, with a CAGR of 10.7%. Anticipated factors include sustained emphasis on patient compliance, ongoing solutions for needle phobia, further quality of life enhancements, improved safety profiles, and reduced risks of infection and injury. Key trends shaping this period include technological advancements, evolution of digital health integration, nanotechnology applications, and the rise of combination therapies.

View More On The Non-injectable Insulin Market Report 2024 – https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Innovative Advancements In Non-Injectable Insulin Delivery

Major companies are innovating in drug delivery technologies to enhance the management of diabetes. For example, needle-free oral insulin sprays offer a painless alternative for blood glucose regulation. NiedlFree Technologies introduced Ozulin, an oral insulin spray in November 2023, aiming to provide a user-friendly option for diabetes management. This innovation could revolutionize treatment by offering a convenient and pain-free alternative to traditional injections.

Abbott Expands Diabetes Care Portfolio With Acquisition Of Bigfoot Biomedical

In September 2023, Abbott Laboratories acquired Bigfoot Biomedical Inc., combining Abbott’s expertise in continuous glucose monitoring with Bigfoot’s smart insulin management systems. This acquisition reinforces Abbott’s leadership in comprehensive diabetes care, aligning with their commitment to advancing connected solutions for precise diabetes management.

Market Segmentation and Regional Insights

The non-injectable insulin market is segmented based on type (synthetic insulin, semi-synthetic insulin), product (pills, sprays, others), and distribution channel (hospital pharmacies, online pharmacies, drug stores). North America dominated the market in 2023, while Asia-Pacific is projected to be the fastest-growing region through the forecast period.

Conclusion

The non-injectable insulin market is expanding rapidly, driven by rising obesity and diabetes rates globally. Innovations in delivery technologies, such as oral insulin sprays, are enhancing treatment options and improving patient outcomes. With significant investments in technological advancements and strategic acquisitions, major companies are poised to capitalize on these opportunities, shaping the future landscape of diabetes management

Request A Sample Of The Global Non-injectable Insulin Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13888&type=smp